Fasching U
Wien Med Wochenschr. 1981 Feb 15;131(3):82-6.
Diflunisal, a new difluorophenyl derivative of salicylic acid was compared with acetylsalicylic acid in 16 patients with rheumatoid arthritis in a double-blind study during 8 weeks. All patients who had taken Diflunisal and showed a good therapeutic response were treated with Diflunisal over additional 24 weeks. Diflunisal showed a statistically significant better efficacy than acetylsalicylic acid in all subjective and objective parameters. Above all the grip strength improved greatly in the Diflunisal group. In the patients who were included in the following 24 week study with Diflunisal the successful treatment could be continued through the whole study period. Day-pain and morning stiffness showed statistically significant improvement. Side effects appeared during the double-blind study only in the acetylsalicylic acid group. The results of the study showed Diflunisal in an average dosage of 500 to 1000 mg per day to be a useful drug in the treatment of rheumatoid arthritis not least due to the negligible side effects.
二氟尼柳，一种新的水杨酸二氟苯基衍生物，在一项为期8周的双盲研究中，与乙酰水杨酸对16例类风湿性关节炎患者进行了比较。所有服用二氟尼柳且显示出良好治疗反应的患者，在接下来的24周内继续用二氟尼柳治疗。在所有主观和客观参数方面，二氟尼柳显示出比乙酰水杨酸有统计学意义的更好疗效。尤其是二氟尼柳组的握力有很大改善。在纳入接下来24周二氟尼柳研究的患者中，整个研究期间都能持续成功治疗。日间疼痛和晨僵有统计学意义的改善。副作用仅在双盲研究期间出现在乙酰水杨酸组。研究结果表明，二氟尼柳平均每日剂量500至1000毫克是治疗类风湿性关节炎的一种有效药物，尤其是因为副作用可忽略不计。
